The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
There is a great opportunity for utilizing traditional medical practices like Ayurveda in Value Based Healthcare
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
A First of its Kind Initiative in Mahbubnagar District for Medical Officers, ANM, Anganwadi workers for prevention of Thalassemia and Sickle Cell anemia as part of Antenatal screening of pregnant women project
APAC to see a reduction in imported surgical robotics
Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient and finished drug at its facilities approved by USFDA
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
